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Summary
 
During episodes of inflammation, polymorphonuclear leukocyte (PMN) transendothelial mi-
gration has the potential to disturb vascular barrier function and give rise to intravascular fluid
extravasation and edema. However, little is known regarding innate mechanisms that dampen
fluid loss during PMN-endothelial interactions. Using an in vitro
 
 
 
endothelial paracellular per-
meability model, we observed a PMN-mediated decrease in endothelial paracellular permeabil-
ity. A similar decrease was elicited by cell-free supernatants from activated PMN (FMLP
10
 
2
 
6 
 
M), suggesting the presence of a PMN-derived soluble mediator(s). Biophysical and bio-
chemical analysis of PMN supernatants revealed a role for PMN-derived 5
 
9
 
-adenosine mono-
phosphate (AMP) and its metabolite, adenosine, in modulation of endothelial paracellular per-
meability. Supernatants from activated PMN contained micromolar concentrations of bioactive
5
 
9
 
-AMP and adenosine. Furthermore, exposure of endothelial monolayers to authentic
5
 
9
 
-AMP and adenosine increased endothelial barrier function more than twofold in both human
umbilical vein endothelial cells and human microvascular endothelial cells. 5
 
9
 
-AMP bioactivity
required endothelial CD73-mediated conversion of 5
 
9
 
-AMP to adenosine via its 5
 
9
 
-ectonucle-
otidase activity. Decreased endothelial paracellular permeability occurred through adenosine A
 
2B
 
 re-
ceptor activation and was accompanied by a parallel increase in intracellular cAMP. We con-
clude that activated PMN release soluble mediators, such as 5
 
9
 
-AMP and adenosine, that
promote endothelial barrier function. During inflammation, this pathway may limit potentially
deleterious increases in endothelial paracellular permeability and could serve as a basic mecha-
nism of endothelial resealing during PMN transendothelial migration.
Key words: adenosine • adenosine monophosphate • ectonucleotidase • endothelium • 
neutrophil
 
N
 
eutrophil-mediated tissue injury is a prominent com-
ponent in organ damage during inflammation (1).
Endothelial cells, which line the inner lumen of blood ves-
sels and largely determine overall vascular permeability, are
primary targets for PMN during uncontrolled inflamma-
tory responses (2). Endothelial injury may result in in-
creased endothelial paracellular permeability and decreased
endothelial barrier function. The resultant local tissue
edema and intravascular loss of fluid and solutes may fur-
ther exacerbate tissue injury via interference with cellular
function and limitation of regional blood flow (3). At
present, mechanisms that may limit fulminant vascular leak
during PMN-endothelial interactions remain largely un-
known.
Although PMN possess an extensive cytotoxic arsenal
(1), their interactions with the endothelium do not inevita-
bly result in increased endothelial paracellular permeability
(4). In fact, in the absence of PMN-endothelial adhesion,
no significant change in endothelial paracellular permeabil-
ity is observed (5, 6), and in vitro models, PMN-mediated
changes in endothelial paracellular permeability do not oc-
cur in the absence of prior endothelial activation (5). En-
dothelial paracellular permeability may remain unchanged
even with transendothelial PMN migration (7). And in vivo,
increased endothelial paracellular permeability is not appar-
ent despite extensive noninflammatory PMN-endothelial ad-
hesion and subsequent transendothelial PMN migration (8).
In this study of PMN–endothelial interactions, we observed
an increase in endothelial barrier function upon exposure
to activated PMN. Further examination revealed that an in-
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crease in barrier function was elicited by a small, stable
PMN-derived soluble mediator(s). Biochemical analysis re-
vealed that 5
 
9
 
-adenosine monophosphate (AMP)
 
1
 
 and adeno-
sine fulfill criteria as PMN-derived bioactive compounds
which promote endothelial barrier function. From this
work, we propose a pathway by which PMN regulate en-
dothelial paracellular permeability during such cell–cell
crosstalk.
 
Materials and Methods
 
Endothelial Cell Isolation and Culture.
 
Human umbilical vein
endothelial cells (HUVEC) were harvested and cultured by a
modification of methods previously described (9, 10). In brief,
HUVEC were harvested with 0.1% collagenase and incubated at
37
 
8
 
C in 95% air/5% CO
 
2
 
. Culture medium was supplemented
with heat-inactivated bovine calf serum, penicillin, streptomycin,
Hepes, heparin, 
 
l
 
-glutamine, and endothelial mitogen factor. For
preparation of experimental HUVEC monolayers, confluent en-
dothelial cells (passages 1, 2, or 3) were seeded at 
 
z
 
2 
 
3
 
 10
 
5
 
 cells/
cm
 
2
 
 onto either permeable polycarbonate inserts or 6-well plates
precoated with 0.1% gelatin. Endothelial cell purity was assessed
by phase microscopic “cobblestone” appearance and uptake of
fluorescent acetylated low density lipoprotein. Human microvas-
cular endothelial cells (HMVEC), a microvascular endothelial
primary culture isolated from adult dermis, were obtained from
Cascade Biologics (Portland, OR) and cultured as recommended.
Where indicated, T84 intestinal epithelial cells were cultured and
passaged as previously described (11).
 
Endothelial Macromolecule Paracellular Permeability Assay.
 
Using
a modification of methods previously described (9), HUVEC or
HMVEC on polycarbonate permeable inserts (0.4-
 
m
 
m pore,
6.5-mm diam; Costar Corp., Cambridge, MA) were studied 7–10 d
after seeding (2–5 d after confluency). Inserts were placed in
HBSS-containing wells (1 ml), and HBSS (alone or with PMN,
PMN supernatant, 5
 
9
 
-AMP, or adenosine) was added to inserts
(150 
 
m
 
l). In experiments using adenosine receptor antagonists,
5
 
9
 
-ectonucleotidase inhibitors, or NBTI, these compounds were
added 20 min before addition of 5
 
9
 
-AMP or adenosine. At the
start of the assay (
 
t
 
 
 
5
 
 0), FITC-labeled dextran 70 kD (concentra-
tion 3.5 
 
m
 
M) was added to fluid within the insert. In experiments
examining HMVEC paracellular permeability, the initial concen-
tration of FITC-labeled dextran 70 kD was increased to 7 
 
m
 
M
due to increased baseline barrier function of HMVEC (
 
z
 
20-fold)
compared with HUVEC. The size of FITC-dextran, 70 kD, ap-
proximates that of human albumin, both of which have been
used in similar endothelial paracellular permeability models (12,
13). Monolayers were stirred via a rotating platform (60 rota-
tions/min, Clinical Rotater; Fisher Scientific Co., Pittsburgh,
PA) and serosal fluid from each well was sampled (50 
 
m
 
l) over 60
min (
 
t
 
 
 
5
 
 5, 10, 15, 20, 30, 60 min); sample volume was replaced
with HBSS. Fluorescence intensity of each sample was measured
(excitation, 485 nm; emission, 530 nm; Cytofluor 2300; Milli-
pore Corp., Waters Chromatography, Bedford, MA) and FITC-
dextran concentrations were determined from standard curves
generated by serial dilution of FITC-dextran. Paracellular flux
was calculated by linear regression of sample fluorescence (Ex-
cel 5.0, Microsoft WA, Power Macintosh 7200; reference 14).
Consistent with observations of other investigators, control ex-
periments demonstrated decreased paracellular permeability with
forskolin and 8-bromo-cAMP (15) and increased paracellular per-
meability with thrombin and hydrogen peroxide (16; data not
shown).
 
Isolation of Human Neutrophils.
 
PMN were freshly isolated
from whole blood obtained by venipuncture from human volun-
teers and anticoagulated with acid citrate/dextrose (11). Plasma
and mononuclear cells were removed by aspiration from the
buffy coat after centrifugation (400 
 
g
 
 
 
3
 
 20 min) at 25
 
8
 
C. Eryth-
rocytes were removed using a 2% gelatin sedimentation tech-
nique. Residual erythrocytes were removed by lysis in cold
NH
 
4
 
Cl buffer. Remaining cells were 
 
.
 
90% PMN as assessed by
microscopic evaluation. PMN were studied within 2 h of their
isolation.
 
PMN-HUVEC Adhesion Assay.
 
PMN, activated with FMLP
(10
 
-6
 
 M), was added to HUVEC grown on permeable inserts. Af-
ter incubation for 60 min at 37
 
8
 
C, each monolayer was gently
washed with 1 ml of Dulbecco’s PBS to remove nonadherent
cells. The contents of each monolayer were then solubilized in
0.5% Triton X-100. Adherent PMN were quantified by myelo-
peroxidase assay (11).
 
Preparation of Activated PMN Supernatants.
 
Freshly isolated PMN
(10
 
8
 
 cells/ml in HBSS with 10
 
-6 
 
M FMLP) were placed in a glass
culture tube and agitated (Adams Nutator; Clay Adams Inc., Nut-
ley, NJ) for one minute. PMN suspensions were then immediately
spun (1,000 
 
g
 
 
 
3 
 
20 s, 4
 
8
 
C), filtered (0.45 
 
m
 
m; Phenomenex, Tor-
rance, CA), and frozen (
 
2
 
80
 
8
 
C) until studied. In experiments mea-
suring supernatant concentrations of 5
 
9
 
-AMP and adenosine,
100-
 
m
 
l samples were taken from PMN suspensions (
 
t
 
 
 
5
 
 0, 1, 2.5,
5, 10, 15, and 20 min), immediately spun (1,000 
 
g
 
 
 
3 
 
20 s, 4
 
8
 
C),
filtered (0.45 
 
m
 
m), and frozen (
 
2
 
80
 
8
 
C) until analysis via HPLC.
 
Measurement of 5-Ectonucleotidase Activity.
 
Based on a modifi-
cation of the method of Bonitati et al. (17), HBSS with or with-
out 1E9 (mAb anti-CD73; 10 mcg/ml), C5/D5 (mAb anti-
CD47; 10 mcg/ml), or APCP (3 
 
m
 
M) was added to HUVEC
monolayers on 6-well plates. After 10 min, E-AMP (10 
 
m
 
M) was
added. After 10 min, fluid was removed, acidified to pH 3.5 with
HCl, spun (1,000 
 
g 
 
3
 
 
 
20 s, 4
 
8
 
C), filtered (0.45 
 
m
 
m), and frozen
(
 
2
 
80
 
8
 
C) until analysis via HPLC. Endothelial 5
 
9
 
-ectonucleoti-
dase activity was assessed by measuring the conversion of E-AMP
to E-ADO.
 
Characterization of PMN-derived Mediators.
 
To estimate the size
range of PMN-derived mediators, activated PMN supernatants
were passed through progressively smaller nominal molecular
mass cut-off filters (Amicon, Danvers, MA) under N
 
2
 
 pressure
(18). To investigate the stability of PMN-derived mediators to
extremes in temperature, activated PMN supernatants were
placed in 1.5-ml eppendorf tubes and either boiled (15 min) or
repeatedly (3
 
3
 
) frozen (
 
2
 
80
 
8
 
C) and thawed.
 
High Performance Liquid Chromatography.
 
A Hewlett-Packard
HPLC (model 1050) with an HP 1100 diode array detector was
used with a reverse phase HPLC column (Luna 5
 
m 
 
C18(2) 150 
 
3
 
4.60 mm; Phenomenex, CA). 5
 
9
 
-AMP was measured with a
NaPhos 0.1 M, pH 6.0, mobile phase (1 ml/min). Adenosine
was measured with a H
 
2
 
O:CH
 
3
 
CN (both with 0.01% acetic acid)
96:4 mobile phase (1 ml/min). E-AMP and E-ADO were mea-
sured with a 0–50% methanol/H
 
2
 
O gradient (10 min) mobile
 
1
 
Abbreviations used in this paper:
 
 ADAC, adenosine amine congener; AMP,
adenosine monophosphate; APCP, 
 
a
 
,
 
b
 
-methylene ADP; CPCA, 5
 
9
 
-(
 
N
 
-
cyclopropyl)-carboxamidoadenosine; CSC, 8-(3-chlorostyryl) caffeine;
E-ADO, ethenoadenosine; E-AMP, ethenoadenosine-5
 
9
 
-monophos-
phate; ECL, enhanced chemiluminescence; HMVEC, human microvas-
cular endothelial cells; HUVEC, human umbilical vein endothelial cells;
NBTI, nitrobenzylthioinosine; NECA, 5
 
9
 
-(
 
N
 
-ethylcarboxamido)adeno-
sine. 
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phase (2 ml/min). Absorbance was measured at 260 nm. UV ab-
sorption spectra were obtained at chromatographic peaks. Aden-
osine and adenine nucleotides were identified by their chromato-
graphic behavior (retention time, UV absorption spectra, and
coelution with standards; 19).
 
CD73 Immunoprecipitation.
 
Confluent cells were labeled with
biotin, lysed, and cell debris removed by centrifugation (9). Lysates
were precleared with 50 
 
m
 
l preequilibrated protein G–Sepharose
(Amersham Pharmacia Biotechnology, Piscataway, NJ). Immu-
noprecipitation of CD73 was performed with mAb 1E9 (1:1,000)
followed by addition of 50 
 
m
 
l preequilibrated protein G–Sepharose
and overnight incubation. Washed immunoprecipitates were
boiled in nonreducing sample buffer (2.5% SDS, 0.38 M Tris, pH
6.8, 20% glycerol, and 0.1% bromophenol blue), separated by
nonreducing SDS-PAGE, transferred to nitrocellulose, and blocked
overnight in blocking buffer. Biotinylated proteins were labeled
with streptavidin-peroxidase and visualized by enhanced chemi-
luminescence (ECL; Amersham Pharmacia Biotechnology).
 
Western Blotting of A
 
2B
 
 Receptor.
 
Confluent cells were lysed
and cell debris removed by centrifugation (9). Samples of lysates
were separated by nonreducing SDS-PAGE, transferred to nitro-
cellulose, and blocked overnight in blocking buffer (250 nM
NaCl, 0.02% Tween-20, 5% normal goat serum, and 3% BSA).
Primary Ab to A
 
2B
 
R (1:1,000 polyclonal; reference 20) was added
for 3 h followed by wash and addition of peroxidase-conjugated
secondary Ab (1:3,000 goat anti–chicken antibody; Kirkegaard &
Perry Laboratories, Inc., Gaithersburg, MD). Labeled bands were
detected by ECL.
 
Intracellular cAMP.
 
HBSS with or without 5
 
9
 
-AMP or aden-
osine was added to HUVEC monolayers on 6-well plates in the
presence of Ro 20-1724 (0.5 mM), a non-xanthine phosphodi-
esterase inhibitor (21). After 15 min, cells were cooled to 4
 
8
 
C,
washed, and cAMP extracted with lysis buffer (EtOH 66%, H
 
2
 
O
33%, Ro 20-1724 0.1 mM). Lysates were cleared by centrifuga-
tion (10,000 
 
g
 
 
 
3
 
 20 min, 4
 
8
 
C), vacuum dried to remove EtOH,
rehydrated in water, and stored (
 
2
 
80
 
8
 
C) until analyzed. Cyclic
AMP was quantitated by a displacement ELISA (Amersham Phar-
macia Biotechnology).
 
Materials.
 
Adenosine was obtained from Calbiochem-Nova-
biochem Corp. (La Jolla, CA). Adenosine amine congener
(ADAC), 59-(N-cyclopropyl)-carboxamidoadenosine (CPCA),
8-(3-chlorostyryl) caffeine (CSC), and alloxazine were obtained
from Research Biochemical International (Natick, MA). Eth-
enoadenosine-59-monophosphate (E-AMP), ethenoadenosine
(E-Ado),  a,b-methylene ADP (APCP), 59-(N-ethylcarboxam-
ido)adenosine (NECA), nitrobenzylthioinosine (NBTI), and 59-
adenosine monophosphate (59-AMP) were obtained from Sigma
Chemical Co. (St. Louis, MO). FITC-dextran was obtained from
Molecular Probes (Eugene, OR). Antibodies 1E9 (mAb anti-
CD73) and anti-A2BR were generous gifts from Dr. Linda Thomp-
son (Oklahoma Medical Research Institute, Oklahoma City,
OK). Antibody C5/D5 (mAb anti-CD47) was raised by the se-
nior author as previously described (22). TranswellÔ inserts were
obtained from Corning Costar Corp. (Cambridge, MA).
Results
Activated PMN and Supernatants Derived from Activated
PMN Decrease Endothelial Paracellular Permeability. To inves-
tigate the influence of activated PMN on endothelial para-
cellular permeability, PMN with FMLP (1026 M) and
FITC-dextran 70 kD were added to HUVEC monolayers
grown on permeable inserts. The maximal PMN dose
(107/monolayer) resulted in a decrease in FITC-dextran
transendothelial flux (Fig. 1). This decrease in FITC-dex-
tran flux occurred despite an increase in PMN–HUVEC
adhesion, as addition of 105, 106, and 107 PMN/monolayer
resulted in 5.8 6 2.0 3 104, 6.6 6 1.8 3 105, 2.5 6 0.7 3
106 adherent PMN/monolayer, respectively. To determine
whether a decrease in paracellular flux was mediated by a
PMN-derived soluble mediator, cell-free supernatants of
activated PMN were added to HUVEC monolayers. Simi-
lar to intact PMN, supernatants of activated PMN de-
creased transendothelial flux of FITC-dextran in a PMN
concentration-dependent manner (Fig. 2, ANOVA, P ,
0.05). Subsequent experiments revealed no apparent en-
dothelial uptake of FITC-dextran, no influence of FMLP
(1026–10210 M) on transendothelial FITC-dextran flux,
and no quenching of FITC-dextran fluorescence by acti-
vated PMN supernatants (data not shown). Therefore, we
concluded that a PMN-derived soluble mediator(s) de-
creases endothelial paracellular permeability.
Activated PMN Supernatants Contain 59-AMP and Adeno-
sine. After demonstrating that a PMN-derived soluble me-
diator(s) promotes endothelial barrier function, we exam-
ined its basic physical and chemical properties. First, to gain
insight into the molecular mass of this mediator(s), acti-
vated PMN supernatants were passed through progressively
smaller molecular mass cut-off filters (range 1–10 kD).
These experiments revealed that supernatants passaged
through filters with a molecular mass cut-off as low as 1
kD, when added to endothelial monolayers, decreased en-
dothelial permeability (51 6 12% decrease in paracellular
permeability compared with control [HBSS]). We next ad-
dressed the stability of this mediator(s). Supernatants that
had undergone boiling or repeated cycles of freeze/thaw,
when added to endothelial monolayers, also decreased en-
dothelial paracellular permeability (38 6 9% and 57 6 8%
decrease in permeability, respectively, compared with con-
trol). These supernatant-mediated reductions in FITC-
Figure 1. Activated PMN decrease
endothelial paracellular permeability.
PMN with FMLP (1026 M) and FITC-
dextran 70 kD were added to monolay-
ers. Transendothelial flux was calculated
by linear regression (6 samples over 60
min) and normalized as percent of con-
trol (HBSS). Data are derived from six
monolayers in each condition; results are
expressed as mean of percent control
flux 6  SEM. An asterisk indicates P ,
0.05 by ANOVA.1436 59-AMP Increases Endothelial Barrier
dextran flux were similar to that elicited by untreated, acti-
vated PMN supernatants (45 6 8%, P 5 NS, ANOVA).
Such findings suggested that the PMN-derived soluble
mediator(s) was a small (,1 kD), stable molecule. These
biophysical features are similar to those of 59-AMP and
adenosine, previously identified PMN-derived factors (18).
Therefore, using HPLC analysis, we examined 59-AMP
and adenosine in PMN supernatants under our defined ac-
tivation conditions (Fig. 3). Indeed, this analysis revealed
59-AMP and adenosine in activated PMN supernatants by
retention times and UV spectra similar to authentic stan-
dards (Fig. 3, insets). Supernatant concentrations of 59-AMP
and adenosine peaked within minutes of PMN activation
(Fig. 4). After 1 min of PMN activation (FMLP 1026 M),
59-AMP concentrations increased from undetectable levels
(,20 nM) to 7.3 6 1.3 mM. The concentration of 59-AMP
declined thereafter, reaching 1.7 6 0.1 mM by 20 min. In
comparison, supernatant concentrations of adenosine reached
a maximum of 4.9 6 0.5 mM at 2.5 min of PMN activa-
tion and declined to 1.4 6 0.3 mM at 20 min. These results
demonstrate that PMN activation results in relatively
high  extracellular concentrations (i.e., micromolar) of both
59-AMP and adenosine. As with other PMN-derived me-
diators, local in vivo concentrations of these compounds
are likely greater due to restricted diffusion from the PMN-
endothelial microenvironment (23, 24).
59-AMP and Adenosine Decrease Endothelial Paracellular
Permeability. After determining that activated PMN su-
pernatants contain micromolar concentrations of 59-AMP
and adenosine, we examined the influence of native com-
pounds on endothelial paracellular permeability. Previous
studies have yielded conflicting results with regard to the
influence of adenosine on endothelial paracellular perme-
ability (21, 25). Furthermore, we are unaware of studies in-
vestigating the influence of 59-AMP on endothelial paracel-
lular permeability. Addition of either 59-AMP or adenosine to
HUVEC monolayers decreased FITC-dextran flux in a
concentration-dependent manner (Fig. 5). Similar results
were observed with the addition of 59-AMP or adenosine
to HMVEC monolayers (Fig. 5). In both endothelial cell
types, the concentration response curves of 59-AMP and
adenosine were equivalent (P 5 NS; ANOVA). In subse-
quent investigations, 59-AMP and adenosine were studied
at their approximate EC50 (50 mM).
Inhibition of HUVEC 59-Ectonucleotidase Attenuates the En-
dothelial Paracellular Permeability Response to 59-AMP. Based on
the equivalent potencies of 59-AMP and adenosine, the ab-
sence of a known purinoreceptor for 59-AMP (26), and the
59-ectonucleotidase enzymatic activity of CD73 in endo-
thelial cells (27), we investigated whether the 59-AMP–
mediated decrease in endothelial paracellular permeability
required conversion of 59-AMP to adenosine at the endo-
thelial cell surface. First, we confirmed the presence of ex-
tracellular CD73 expression in this model. As shown in
Fig. 6 A, a z70-kD cell surface protein consistent with
CD73 was immunoprecipitated in HUVEC and HMVEC
by the mAb 1E9, similar to that immunoprecipitated from
T84 cells, an intestinal epithelia cell line in which CD73 is
constitutively expressed (28). Next, 59-AMP was added to
HUVEC monolayers pretreated with increasing concentra-
tions of the 59-ectonucleotidase inhibitor APCP (29; Fig. 6
B). Pretreatment with APCP diminished (300 nM) or abol-
ished (3 mM) the 59-AMP–mediated decrease in endothe-
lial paracellular permeability. Furthermore, pretreatment
with APCP (3 mM) did not influence the adenosine-medi-
ated decrease in permeability (52 6 12% without APCP vs.
48 6 14% with APCP; [adenosine] 5 50 mM). Addition-
ally, we examined the influence of the anti-CD73 mAb
Figure 2. Supernatants from acti-
vated PMN decrease endothelial para-
cellular permeability. Confluent HU-
VEC on permeable supports were
exposed (apical surface only) to cell-
free supernatants from activated
(FMLP 1026 M) PMN. Supernatants
from activated PMN were added to
monolayers. Supernatants, undiluted
or diluted (as indicated) decreased
transendothelial flux of FITC-dextran
(*P  ,  0.05 vs. control [HBSS];
ANOVA). Supernatants (undiluted)
decreased flux by 50 6 7%. Data are
from 10 monolayers in each condi-
tion. Results are expressed as mean re-
duction in permeability 6 SEM.
Figure 3. Chromatographic identification
of 59-AMP and adenosine in activated
PMN supernatants. 59-AMP and adenosine
were identified by their characteristic reten-
tion times and UV absorption spectra. Rep-
resentative chromatograms and UV spectra
(insets) of authentic 59-AMP (A) and aden-
osine (B) standards are shown by dashed
lines. Representative chromatograms and
UV spectra of activated PMN supernatants
are shown by solid lines.1437 Lennon et al.
(1E9; 10 mg/ml) on 59-AMP bioactivity (Fig. 6 C). Pre-
treatment of HUVEC monolayers with 1E9 abolished ([59-
AMP] 5 10 mM) or attenuated ([59-AMP] 5 100 mM, 1
mM) the 59-AMP–mediated decrease in permeability. In
contrast, 1E9 pretreatment (10 mg/ml) of HUVEC did not
influence the adenosine-mediated decrease in permeability
(Fig. 6 C). Furthermore, pretreatment of HUVEC with
C5/D5 (10 mg/ml), an anti-CD47 endothelial binding
control mAb (22), did not influence the 59-AMP–mediated
decrease in endothelial paracellular permeability (62 6 4%
without C5/D5 vs. 58 6 5% with C5/D5; [59-AMP] 5 1
mM). Prior reports have suggested that 1E9 inhibits 59-ecto-
nucleotidase activity in a human endothelial cell line (30)
but may not inhibit 59-ectonucleotidase activity in placen-
tal tissue (27). Therefore, using HPLC analysis of CD73
substrate, we examined 1E9 inhibition of HUVEC 59-ecto-
nucleotidase activity by measuring endothelial conversion
of the adenine nucleotide E-AMP to E-ADO (17; Fig. 6
D). After pretreatment with 1E9 (10 mg/ml), 59-ectonucleo-
tidase activity decreased by 58 (4% vs. HBSS. By compari-
Figure 4. 59-AMP and adenosine concentrations in activated PMN su-
pernatants. PMN (108/ml) were activated in HBSS with FMLP (1026 M)
in glass tubes. PMN suspensions were sampled at indicated time points af-
ter activation. 59-AMP and adenosine concentrations were measured via
HPLC. Data are from eight donors. Results are expressed as mean con-
centration 6 SEM.
Figure 5. 59-AMP and adenosine decrease endothelial paracellular per-
meability. 59-AMP or adenosine were added to HUVEC monolayers
(left) or HMVEC monolayers (right). Both 59-AMP and adenosine de-
creased transendothelial FITC-dextran flux in a dose-dependent manner
(*P , 0.05; ANOVA). 59-AMP and adenosine were equally potent. Data
are from 6–8 monolayers in each condition. Results are expressed as mean
6 SEM.
Figure 6. 59-Ectonucleotidase inhibition reverses the 59-AMP–medi-
ated decrease in endothelial paracellular permeability. (A) CD73 is expressed
on the cell surface of confluent HUVEC and HMVEC as demonstrated
by mAb 1E9 immunoprecipitation of biotinylated protein (arrow). CD73
was also immunoprecipitated from confluent T84 cells, an intestinal epi-
thelia cell line previously known to express this ectoenzyme. (B) Addition
of 59-AMP to HUVEC monolayers decreased transendothelial FITC-dextran
flux (*P , 0.05 vs. HBSS; ANOVA). APCP, a 59-ectonucleotidase inhib-
itor, reversed this decrease in endothelial paracellular permeability (‡P ,
0.05; ANOVA). Data are from six monolayers in each condition. (C) Ad-
dition of 59-AMP or adenosine to HUVEC monolayers decreased
transendothelial FITC-dextran flux (*P , 0.05 vs. control [HBSS];
ANOVA). 1E9, an anti-CD73 mAb, attenuated this decrease in perme-
ability for 59-AMP but not for adenosine (‡P , 0.05 vs. no 1E9;
ANOVA). Data are from 8 monolayers in each condition. (D) HUVEC
59-ectonucleotidase activity was decreased (*P , 0.05 vs. control) by
APCP (3 mM) or 1E9 (10 mcg/ml) pretreatment. Data are from 12
monolayers in each condition. Results are expressed as mean 6 SEM.1438 59-AMP Increases Endothelial Barrier
son, pretreatment with anti-CD47 mAb C5/D5 did not
influence 59-ectonucleotidase activity. These results suggest
a prominent role for endothelial CD73 59-ectonucleotidase
activity in the 59-AMP–mediated decrease in endothelial
paracellular permeability.
Endothelial Paracellular Permeability Response to 59-AMP Is
Mediated via Adenosine Receptor Activation. Based on our ob-
servations that the mechanism of the 59-AMP–mediated
decrease in endothelial paracellular permeability may in-
volve extracellular conversion of 59-AMP to adenosine, the
role of adenosine receptor activation was examined. HU-
VEC monolayers were pretreated (12 h) with NECA, a
nonmetabolizable and potent nonselective adenosine re-
ceptor agonist; such pretreatment desensitizes adenosine re-
ceptor-mediated responses (28). Pretreatment with NECA
diminished (300 nM) or abolished (3 mM) the 59-AMP
mediated decrease in endothelial paracellular permeability
(Fig. 7). Because endothelial cells are also capable of rapid
cellular uptake of extracellular adenosine (31), the potential
role of endothelial cell signaling via adenosine uptake was
examined. HUVEC monolayers were pretreated with ni-
trobenzylthioinosine (NBTI, 10 mM) before the addition
of 59-AMP; NBTI is an inhibitor of facilitated membrane
transport of purine nucleotides (32). Pretreatment with
NBTI did not influence the 59-AMP–mediated reduction
in permeability (53 6 5% with NBTI vs. 47 6 4% without
NBTI; [59-AMP] 5 50 mM). Therefore, the 59-AMP–
mediated decrease in permeability was not dependent upon
endothelial adenosine uptake. We conclude from these data
that 59-AMP decreases endothelial paracellular permeability
via its extracellular conversion to adenosine and subsequent
endothelial adenosine receptor activation.
59-AMP Decreases Endothelial Paracellular Permeability via
Adenosine A2B Receptor Activation. To further define the
purine receptor involved in the adenosine-mediated de-
crease in endothelial paracellular permeability, increasing
concentrations of either the A1-specific agonist ADAC or
the A2-specific agonist CPCA were examined in our en-
dothelial paracellular permeability model (Fig. 8). Whereas
the A1 agonist ADAC did not influence FITC-dextran trans-
endothelial flux, the A2 agonist CPCA decreased flux in a
manner similar to 59-AMP and adenosine. At present, a spe-
cific A2B receptor agonist is not available (20). Therefore,
A2A and A2B receptor antagonists were used to further define
the A2 receptor subtype. 59-AMP was added to HUVEC
monolayers pretreated with increasing concentrations of
either CSC (A2A antagonist) or alloxazine (A2B antagonist;
Fig. 9). Whereas pretreatment with CSC had no significant
influence (Fig. 9 A), pretreatment with alloxazine signifi-
cantly diminished the 59-AMP–mediated decrease in en-
dothelial paracellular permeability (B). We conclude that
59-AMP decreases permeability via conversion to adeno-
sine with subsequent adenosine A2B receptor activation.
Western blot analysis confirmed the presence of the adeno-
sine A2B receptor in both HUVEC and HMVEC (Fig. 9 C),
similar to T84 intestinal epithelia cells (20).
59-AMP and Adenosine Increase Levels of Endothelial
cAMP. Activation of adenosine A2 receptors results in in-
creased intracellular levels of cAMP via stimulation of ade-
nylate cyclase through receptor interaction with Gas (26).
Therefore, adenylate cyclase activity in response to 59-
AMP (50 mM) or adenosine (50 mM) was investigated by
determining the cumulative production of cAMP over 15
min in the presence of the non-xanthine phosphodiesterase
inhibitor Ro 20-1724 (0.5 mM; reference 21). Compared
with control (HBSS), administration of 59-AMP and ade-
nosine resulted in similar increases in intracellular cAMP
levels (287 6 23% and 321 6 21% increase, respectively),
suggesting that 59-AMP and adenosine are equipotent in
their stimulation of adenylate cyclase activity.
Discussion
Endothelial cells, the primary determinants of vascular
permeability (33), may suffer PMN-mediated injury and
dysfunction during inflammation. Such injury and dysfunc-
tion is typically manifested by a decrease in endothelial bar-
Figure 7. NECA pretreat-
ment reverses the 59-AMP–
mediated decrease in endothelial
paracellular permeability. Addi-
tion of 59-AMP (50 mM) to
HUVEC monolayers decreased
transendothelial FITC-dextran
flux (*P , 0.05 vs. HBSS). Pre-
treatment of HUVEC monolay-
ers with NECA diminished
([NECA]  5  300 nM) or abol-
ished ([NECA] 5 3 mM) this
decrease in flux (‡P , 0.05 vs.
59-AMP without NECA). Data
are from eight monolayers in
each condition. Results are ex-
pressed as mean 6 SEM.
Figure 8. Adenosine A2 receptor
activation decreases endothelial para-
cellular permeability. ADAC and
CPCA, adenosine receptor agonists,
were added to HUVEC monolayers.
Only CPCA (A2 agonist) decreased
transendothelial FITC-dextran flux
(*P  ,  0.05 vs. control [HBSS]). Data
are from 6–8 monolayers in each con-
dition. Results are expressed as mean
6 SEM.1439 Lennon et al.
rier function (2). In this study, we examined the influence
of PMN on endothelial paracellular permeability. This
study revealed that intact PMN promote endothelial barrier
function. Similarly, small (,1 kD), stable PMN-derived
mediators also promote endothelial barrier function. These
soluble mediators were identified as 59-AMP and adenosine
based on their physical and chemical characteristics and
chromatographic behavior. Further studies revealed that
59-AMP undergoes conversion to adenosine at the endo-
thelial cell surface. Adenosine, whether from CD73-medi-
ated conversion of 59-AMP or PMN-derived, activates A2B
receptors, increases intracellular cAMP, and results in in-
creased endothelial barrier function.
Neutrophil-mediated endothelial cell injury may occur
during inflammation but requires PMN-endothelial cell
adhesion (5, 6). However, PMN-endothelial adhesion does
not necessarily result in endothelial injury. For example, in
vitro, PMN-endothelial adhesion or transendothelial PMN
migration does not lead to increased permeability without
prior endothelial cell activation (5, 7, 34). Furthermore, in
vivo, z100 billion PMN normally exit the circulation per
day (8) via PMN-endothelial cell adhesion and transendothe-
lial PMN migration, without clear adverse consequences.
In the studies presented here, PMN interactions with un-
activated endothelium resulted in enhanced endothelial
barrier function. To eliminate the possible direct physical
obstruction to tracer flux by PMN, we examined the influ-
ence of cell-free supernatants from activated PMN. Under
these conditions, PMN supernatants increased endothelial
barrier function by as much as twofold. Thus, activated
PMN release soluble mediators that dramatically promote
endothelial barrier function. This is the first report of
PMN-mediated enhancement of endothelial barrier func-
tion and is contrary to the dogma that PMN-endothelial
interactions result in endothelial injury. Other investigators
using similar models have not observed such an influence
of activated PMN or activated PMN supernatants (35, 36),
possibly due to their use of lower PMN concentrations. In-
deed, in these experiments, low numbers of PMN (105 or
106 per monolayer) or dilute PMN supernatants (.1:8 di-
lution) failed to influence endothelial paracellular perme-
ability, suggesting that these PMN-derived soluble media-
tors act locally.
Upon activation, PMN release numerous compounds,
either via exocytosis of intracellular granules or directly
across the cellular membrane (37). Based on biophysical
features of this PMN-derived mediator (i.e., stable, MW
,1 kD) and previous work demonstrating actions of
PMN-derived 59-AMP and its metabolite, adenosine, in an
epithelial cell model (18), we measured concentrations of
these compounds in supernatants from activated PMN.
Concentrations of 59-AMP and adenosine were in a range
sufficient to influence endothelial paracellular permeability.
However, because the concentrations of these compounds
in supernatants do not fully account for the observed changes
in endothelial paracellular permeability, their effects are
likely augmented by or additive with other, unidentified
PMN-derived compounds. As with other PMN-derived
mediators, local concentrations of 59-AMP and adenosine
are greater within the PMN-endothelial microenviron-
ment (23, 38). The elevated concentrations of 59-AMP in
activated PMN supernatants are likely due to extracellular
metabolism of ATP and ADP released by viable PMN (39,
40). Similarly, the elevated concentrations of adenosine in
activated PMN supernatants are likely due to extracellular
metabolism of PMN-derived 59-AMP (40). The mecha-
nisms by which PMN release adenine nucleotides and adeno-
sine into the extracellular environment are not clearly de-
fined but appear to involve direct transport or diffusion
across the cell membrane (19). The concentrations of 59-AMP
and adenosine in activated PMN supernatants reported
here are consistent with those reported by others (18, 39),
and as with previous reports (39), even higher concentra-
tions of these compounds were observed upon PMN acti-
vation with PMA (data not shown).
Although we investigated PMN-derived 59-AMP and
adenosine, other cell types may contribute to intravascular
concentrations of these compounds and thereby modulate
endothelial paracellular permeability. Endothelial cells them-
selves release adenine nucleotides and adenosine (19) that
Figure 9. Adenosine A2B receptor antag-
onist diminishes the 59-AMP–mediated de-
crease in endothelial paracellular permeabil-
ity. Addition of 59-AMP (50 mM) to
HUVEC monolayers resulted in a decrease
in transendothelial FITC-dextran flux (*P ,
0.05 vs. control [HBSS]). (A) CSC (A2A re-
ceptor antagonist) had no effect on the 59-
AMP–mediated decrease in endothelial
paracellular permeability. (B) Alloxazine
(A2B receptor antagonist) inhibited the 59-
AMP–mediated decrease in endothelial
paracellular permeability (B; ‡P , 0.05 vs.
59-AMP only). Data are from eight mono-
layers in each condition; results are ex-
pressed as mean 6 SEM. (C) Adenosine A2B
receptor is present in confluent HUVEC,
HMVEC, and T84 cells as shown by cell ly-
sate Western blot (arrow).1440 59-AMP Increases Endothelial Barrier
have the potential to influence permeability through an
autocrine pathway. Eosinophils also release 59-AMP and
adenosine in quantities similar to that produced by PMN
(41). Platelets release adenine nucleotides and adenosine
(42). Platelet-derived ATP and ADP concentrations may
reach 20 mM in serum and even higher (i.e., mM) at the
endothelial cell surface (43). Through endothelial cell sur-
face conversion of ATP and ADP to 59-AMP via ecto-
ATP diphosphohydrolase (CD39; reference 44) and subse-
quent conversion to adenosine via 59-ectonucleotidase/
CD73, such platelet-derived ATP and ADP may indirectly
modulate endothelial paracellular permeability (44). Similar
enzymatic conversion of ATP to adenosine may modulate
endothelial paracellular permeability in conditions where
serum ATP concentrations reach 20–100 mM such as organ
injury (45) and traumatic shock (46).
Endothelial cell surface metabolism of 59-AMP to adeno-
sine requires 59-ectonucleotidase/CD73; other ectonu-
cleotidases are not capable of metabolizing 59-AMP (44).
Through inhibition of endothelial 59-ectonucleotidase/
CD73 with APCP or mAb 1E9, our data demonstrate that
the 59-AMP–mediated decrease in endothelial paracellular
permeability requires endothelial cell surface conversion of
59-AMP to adenosine. The competitive inhibitor APCP
abolished the influence of 59-AMP, whereas the less po-
tent, noncompetitive inhibitor mAb 1E9 substantially di-
minished the influence of 59-AMP. In comparison, neither
59-ectonucleotidase/CD73 inhibitor had any influence on
the adenosine-mediated decrease in endothelial paracellular
permeability. Thus, 59-ectonucleotidase/CD73 influences
endothelial cell permeability in addition to its previously
characterized role as a cell adhesion molecule (47). This
role of 59-ectonucleotidase in modulating endothelial para-
cellular permeability via conversion of 59-AMP to adeno-
sine and subsequent adenosine receptor activation is sup-
ported by its previously reported roles in modulating the
intestinal chloride secretory effects of PMN-derived 59-
AMP (18) and the anti-inflammatory effects of endothelial-
derived 59-AMP (19). Although this study was restricted to
the role of endothelial CD73 in the 59-AMP–mediated de-
crease in endothelial paracellular permeability, other cell
types may also enhance this 59-AMP–mediated decrease in
endothelial paracellular permeability. For example, PMN
have themselves been demonstrated to contribute 59-ecto-
nucleotidase activity (40). At present, it is not known whether
such 59-ectonucleotidases are regulated or whether such
regulation contributes to modulation of vascular perme-
ability in vivo. The CD73 promoter contains a binding site
for the nuclear transcription factor NF-kB (48), establish-
ing the possibility that this enzyme may be regulated by
proinflammatory mediators (17). Such a mechanism is well
established for other endothelial proteins (49).
Adenosine A2B receptor activation, either directly by
adenosine or after conversion of 59-AMP, results in an in-
crease in endothelial barrier function. This increase in en-
dothelial barrier function is the opposite of that expected
with endothelial injury but is consistent with adenosine’s
other, antiinflammatory roles. Although adenosine pro-
motes PMN chemotaxis and PMN-endothelial adherence
at low concentrations (i.e., picomolar), adenosine at higher
concentrations (i.e., nanomolar) decreases PMN reactive
oxygen species and leukotriene generation and inhibits
PMN-endothelial adhesion (50, 51). These latter direct ef-
fects of adenosine on PMN function may account for the
inhibition of PMN-mediated organ injury observed with
adenosine administration both in vitro (52) and in vivo
(53). Therefore, adenosine may also indirectly promote en-
dothelial barrier function during inflammation via inhibi-
tion of PMN cytotoxicity. Other direct antiinflammatory
effects of adenosine include inhibition of monocyte and
endothelial release of inflammatory cytokines, inhibition of
endothelial cell adhesion molecule expression, inhibition of
PMN leukotriene biosynthesis, and activation of cellular
antioxidant defense systems (51, 54). Adenosine’s antiin-
flammatory effects extend into the postinflammatory phase
via its promotion of wound healing (55). Thus, the adeno-
sine-mediated increase in endothelial barrier function dem-
onstrated in this study appears to represent part of an over-
all antiinflammatory role of this molecule (54).
In our model, adenosine primarily derived from 59-AMP
promoted endothelial barrier function. Adenosine receptor
subtypes may be classified as A1, A2A, A2B, or A3. The pres-
ence of A2B receptors in HUVEC was demonstrated by
RT-PCR by Montesinos (55) and confirmed by Western
blot in this study. Adenosine A2 receptor activation (either
A2A or A2B) increases intracellular levels of cAMP via stim-
ulation of adenylate cyclase and receptor interaction with
Gas (26), whereas adenosine A1 or A3 receptor activation
decreases intracellular levels of cAMP. In our model, aden-
osine decreased endothelial paracellular permeability and
increased intracellular levels of cAMP via adenosine A2B re-
ceptor activation. Therefore, our observations are consis-
tent with the known consequences of adenosine A2 recep-
tor activation and prior observations demonstrating a close
association between endothelial paracellular permeability
antagonists and increased intracellular cAMP (56). Previous
studies have yielded conflicting results on the influence of
adenosine receptor activation on endothelial paracellular
permeability. These differences may be due to differences
in endothelial cell origin or proportional expression of adeno-
sine receptor subtypes (21, 25). Our data do not explain the
dependence of enhanced endothelial barrier function upon
activation of low-affinity A2B receptors rather than activa-
tion of high-affinity A2A receptors (26). Possibly, this differ-
ence may be due to either increased HUVEC A2B receptor
expression or intracellular cAMP compartmentalization.
Although the mechanism by which adenosine A2B re-
ceptor activation decreases endothelial paracellular perme-
ability is not clear, it is attractive to propose that it is medi-
ated through increased levels of intracellular cAMP for the
following reasons. First, activation of adenosine A2B recep-
tors increase intracellular cAMP (26). And second, there is
an association between permeability antagonists and in-
creased intracellular cAMP (56). In endothelial cells from
different origins, increased intracellular cAMP (and de-
creased permeability) is accompanied by a rapid increase in1441 Lennon et al.
polymerized actin, an increase in cell surface area, a loss of
stress fibers, and increased phosphorylation of intermediate
filaments, suggesting that cAMP–mediated changes in en-
dothelial paracellular permeability may be due to alterations
in cellular cytoskeleton (57). In turn, these cytoskeletal al-
terations most likely are dependent upon the activity of
Rho GTPase proteins (58). Ultimately, these intracellular
processes alter endothelial paracellular permeability via
their actions on the intercellular junctions (59). Tight junc-
tions and adherens junctions determine paracellular perme-
ability in endothelial cells (4). In endothelial cells where
baseline permeability is relatively high such as in HUVEC,
organized tight junctions are not expressed and therefore,
adherens junctions may be the predominate determinant of
permeability (5). The importance of adherens junctions in
determining endothelial paracellular permeability is sup-
ported by recent observations of a close correlation of per-
meability with phosphorylation of VE-cadherin, an adher-
ens junction protein (60).
Therefore, based on the data presented here, we propose
that PMN-derived 59-AMP decreases endothelial paracellu-
lar permeability via CD73-mediated conversion of 59-AMP
to adenosine (Fig. 10). Adenosine, whether from endothe-
lial CD73-mediated conversion of 59-AMP or PMN-
derived, activates endothelial adenosine A2B receptors. Re-
ceptor activation stimulates adenylate cyclase and leads to
an increase in intracellular cAMP. This increase in cAMP
results in cytoskeletal changes that decrease paracellular
permeability via actions at interendothelial junctions. This
decrease in endothelial paracellular permeability prevents
edema and intravascular loss of fluid and solutes. Such a
model suggests an inherent mechanism to dampen in-
creased endothelial paracellular permeability during PMN-
endothelial interactions.
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